<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00837720</url>
  </required_header>
  <id_info>
    <org_study_id>NIS-CSI-ATA-2005/1</org_study_id>
    <nct_id>NCT00837720</nct_id>
  </id_info>
  <brief_title>Evaluation of Atacand® (Candesartan) in Daily Medical Practice</brief_title>
  <official_title>A 12-Week Open-Label Non-Interventional Evaluation of Atacand® (Candesartan) Efficacy, Tolerability, Compliance and Treatment Satisfaction in Patients With Arterial Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This open label, non-interventional study is to show the efficacy of antihypertensive
      treatment with Atacand in hypertensive patients. Efficacy is to be evaluated based on the
      difference in systolic and diastolic blood pressure at baseline and at both follow-up visits.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2006</start_date>
  <completion_date type="Actual">June 2007</completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Systolic and diastolic blood pressure reduction</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence and reasons of treatment discontinuation</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient treatment satisfaction (using 5-point answering scale) as the measure of the patient's overall tolerance</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physician overall evaluation of the therapy (using 5-point answering scale)</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">750</enrollment>
  <condition>Hypertension</condition>
  <eligibility>
    <study_pop>
      <textblock>
        patients (outpatient or hospitalised) in whom Atacand is indicated according to the current
        Summary of product characteristics (SPC)
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  a patient with arterial hypertension who has been prescribed Atacand according to
             physician's judgement, irrespective of the inclusion in the study

        Exclusion Criteria:

          -  hypersensitivity to candesartan or any other ingredient of Atacand

          -  liver function impairment and/or cholestasis

          -  severe renal insufficiency

          -  woman of child-bearing potential and not using appropriate contraceptive measures,
             pregnancy or lactation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rok Accetto, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Medical Centre Ljubljana</affiliation>
  </overall_official>
  <verification_date>February 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 4, 2009</study_first_submitted>
  <study_first_submitted_qc>February 4, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 5, 2009</study_first_posted>
  <last_update_submitted>February 5, 2009</last_update_submitted>
  <last_update_submitted_qc>February 5, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 6, 2009</last_update_posted>
  <responsible_party>
    <name_title>Meta Jeras, Mr Ph, Regulatory and Medical Affairs Manager</name_title>
    <organization>AstraZeneca</organization>
  </responsible_party>
  <keyword>hypertension</keyword>
  <keyword>blood pressure</keyword>
  <keyword>Atacand®</keyword>
  <keyword>candesartan</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Candesartan</mesh_term>
    <mesh_term>Candesartan cilexetil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

